NCT01474551View on ClinicalTrials.gov

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Melanoma
Interventions
DRUG

vemurafenib

All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER